Sort   by:  
 Page size 
MetabolomicsSex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype (UPLC-MS RP POS assay)

Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic tar...

2020-03-19 | MTBLS1129 | MetaboLights
MetabolomicsSex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype (UPLC-MS RP NEG assay)

Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic tar...

2020-03-19 | MTBLS1130 | MetaboLights
MetabolomicsSex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype (UPLC-MS HILIC NEG assay)

Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic tar...

2020-03-19 | MTBLS1124 | MetaboLights
MetabolomicsSex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype (UPLC-MS HILIC POS assay)

Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic tar...

2020-03-19 | MTBLS1122 | MetaboLights
MetabolomicsPlasma Lipid Profile Reveals Plasmalogens as Potential Biomarkers for Colon Cancer Screening

In this era of precision medicine, there is an increasingly urgent need for highly sensitive tests for detecting tumors such as colon cancer (CC), a silent disease where the first symptoms may take 10-15 yr to appear. Mass spectrometry-based lipidomics is an emerging tool for such clinical diagno...

2023-11-13 | MTBLS1584 | MetaboLights
MetabolomicsDistinct microbes, metabolites, and the host genome define the multi-omics profiles in right-sided and left-sided colon cancer

BACKGROUND: Studies have reported clinical heterogeneity between right-sided colon cancer (RCC) and left-sided colon cancer (LCC). However, none of these studies used multi-omics analysis combining genetic regulation, microbiota and metabolites to explain the site-specific differ...

2024-12-16 | MTBLS10232 | MetaboLights
MetabolomicsExtracts from sweet sorghum (Sorghum bicolor), a feedstock for biorefining, suppressed proliferation and elevated apoptosis in human colon cancer stem cells via suppression of Wnt/beta-catenin signaling pathway
In colorectal cancer, p53 is commonly inactivated, associated with chemo-resistance, and marks the transition from non-invasive to invasive disease. Cancers, including colorectal cancer, are thought to be diseases of aberrant stem cell populations, as stem cells are able to self-renew, making them l...
2014-05-01 | MTBLS69 | MetaboLights
MetabolomicsAspirin Metabolomics in Colorectal Cancer Chemoprevention (part 1 - Colon)
Not available
ORGANISM(S): Homo sapiens 
ST001091 | MetabolomicsWorkbench
MetabolomicsColon cancer metabolomics via stool sample
Not available
ORGANISM(S): Mus musculus 
ST000371 | MetabolomicsWorkbench
TranscriptomicsEpigenomic enhancer profiling defines a signature of colon cancer
This SuperSeries is composed of the following subset Series: GSE36204: Epigenomic enhancer profiling defines a signature of colon cancer [ChIP-seq] GSE36400: All exon array expression data in normal colon and primary colon cancer lines [expression] Refer to individual Series
ORGANISM(S): Homo sapiens 
2012-04-15 | E-GEOD-36401 | biostudies-arrayexpress
Sort   by:  
 Page size